Compare Amylx Pharmaceuticals Inc (AMLX) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Waste Management, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B), while Waste Management, Inc. trades at $227.34 (market cap $90.68B). The key difference: Waste Management, Inc. is far larger — about 34.3× Amylx Pharmaceuticals Inc's market cap, and Waste Management, Inc. pays a 1.56% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | WM | |
|---|---|---|
Market Cap | $2.64B | $90.68B |
Sector | Health | Industrials |
52-Week High | $24.19 | $246.51 |
52-Week Low | $7.82 | $196.77 |
Enterprise Value | $2.39B | $113.47B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
WM trades at $227.2, up 0.26% on the day, with a neutral technical signal and strong analyst support. The company reported Q2 2026 EPS of $2.02, beating estimates, and maintains robust profitability with a net income margin of 11.12%. Revenue growth is steady, reaching $25.20B in 2025, though valuation multiples like a P/E of 59.74 appear elevated. Recent news highlights institutional trading activity and earnings focus on pricing discipline.
The outlook is positive with a consensus price target of $263.43, implying 16% upside, supported by 57% buy ratings. Risks include high debt levels and sensitivity to economic cycles, but consistent cash flow generation and margin gains provide a solid foundation for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
